



GOBIERNO DE LA CIUDAD DE BUENOS AIRES

Informe

Número:

Buenos Aires,

Referencia: Proyecto de Ley - Declara Ciudadano Ilustre de la Ciudad Autónoma de Buenos Aires al Dr. Fernando Polack.

PROYECTO DE LEY

Artículo 1°.- Declarar Ciudadano Ilustre de la Ciudad Autónoma de Buenos Aires al Dr. Fernando Polack.

Artículo 2°.- Comuníquese, etc

FUNDAMENTOS

Tengo el agrado de dirigirme al Cuerpo Legislativo a fin de poner a consideración de la Legislatura de la Ciudad Autónoma de Buenos Aires un proyecto de Ley que tiene por objeto declarar Ciudadano Ilustre de la Ciudad Autónoma de Buenos Aires al Dr. Fernando Polack, en virtud de su sobresaliente trayectoria profesional, prestigio internacional, compromiso social y contribución significativa a la inclusión laboral de las personas con discapacidad.

El Dr. Fernando Polack nació el 6 de marzo de 1967 en la Ciudad Autónoma de Buenos Aires. Es un reconocido médico pediatra e infectólogo, investigador clínico y científico, graduado con honores en la Facultad de Medicina de la Universidad de Buenos Aires (UBA) en el año 1990.

Se formó como infectólogo en Johns Hopkins School of Medicine, el hospital más prestigioso de Estados Unidos y luego continuó otros siete años como profesor titular de Pediatría y Vacunas en la Universidad Vanderbilt.

Dentro del ámbito académico se destaca su labor como Profesor Asistente, de la División de Enfermedades Infecciosas, Departamento de Pediatría, Facultad de Medicina, Universidad Johns Hopkins (1999–2006); Profesor Asociado, División de Enfermedades Infecciosas, Departamento de Pediatría, Universidad Johns Hopkins (2006–2009); Director, Red Panamericana de Infancia, Universidad Johns Hopkins (2006–2009); Profesor Asociado, División de Enfermedades Infecciosas, Departamento de Pediatría, Universidad Vanderbilt (2009–2011), Titular de la Cátedra César Milstein, Vanderbilt Vaccine Center, Universidad Vanderbilt (2009–2016); Profesor Titular, División de Enfermedades Infecciosas, Departamento de Pediatría, Universidad Vanderbilt (2011–2016).

En 2003 fundó INFANT, una organización sin fines de lucro dedicada a la investigación biomédica, al estudio de enfermedades respiratorias en la infancia y a la implementación de intervenciones innovadoras destinadas a mejorar la salud de poblaciones vulnerables. La Fundación proveyó datos críticos para el desarrollo seguro de vacunas, obteniendo subsidios por dos décadas del NIH, la Fundación Bill & Melinda Gates y el CONICET. INFANT surgió con la intención de trasladar los hallazgos científicos en acciones médicas que mejoran la salud de los niños. A través de INFANT se formaron decenas de profesionales, muchos de los cuales se encuentran actualmente trabajando en

salud pública, investigación, docencia y hospitales. Esto representa un legado institucional que fortalece la ciencia local. Los proyectos de la fundación cuentan con el soporte y reconocimiento de prestigiosas instituciones nacionales e internacionales.

El Dr. Polack publicó más de un centenar de manuscritos en revistas de alto impacto y participó como disertante en numerosas conferencias internacionales.

Respecto a sus reconocimientos, recibió el Premio a la Excelencia en Investigación y al Investigador Pediátrico Joven por la Sociedad de Investigación Pediátrica y la Sociedad de Pediatría de los Estados Unidos; The Thomas and Carol McCann Award in Respiratory Research, de la Johns Hopkins School of Public Health y el Pasteur Mérieux Connaught Laboratories Fellowship in Pediatrics del la Infectious Diseases Society of America. En Argentina, el B'nai B'rith en los Human Rights Award; Premio Luis Pasteur, O.S. Sanidad, Academia Nacional de Medicina.

El 16 de diciembre de 2008 se publicó la Ley 2.929, que lo declaró personalidad destacada de la ciencia, por su trayectoria y compromiso en traducir los hallazgos de laboratorio producidos en el desarrollo de iniciativas científicas en acciones de impacto directo para la salud de los niños.

En 2020, durante la pandemia de COVID-19, su equipo en Argentina participó en ensayos clínicos claves de vacunas y tratamientos, aportando al conocimiento global sobre prevención y mitigación, lo que demuestra su compromiso con la salud colectiva en momentos críticos.

Asimismo, el Dr. Polack fue fundador de Alamesa, el primer restaurante de Argentina atendido y gestionado íntegramente por jóvenes neurodiversos, situado en el barrio de Palermo, en la calle Maure 1643.

Este proyecto nació de la preocupación y necesidad de mejorar la inserción laboral de las personas con discapacidad. Constituye un antecedente innovador en materia de accesibilidad y autonomía, al promover la participación activa de personas con discapacidad en tareas productivas y creativas vinculadas con la gastronomía y la hospitalidad. A través de la capacitación, el acompañamiento y los apoyos adecuados, se promueve no solo un entorno de pertenencia sino el desarrollo de habilidades, la participación plena en la vida social y la construcción de un proyecto de vida independiente. Actualmente cuenta con 40 empleados y una lista de espera de 1400 personas. En este sentido, su visión coincide con los principios rectores de la Ciudad Autónoma de Buenos Aires en materia de inclusión de personas con discapacidad, ya que impulsa iniciativas que consideran la diversidad de necesidades de la población y fomentan el diseño de intervenciones accesibles.

Alamesa recibió reconocimientos de la Secretaría de Turismo, esta Legislatura, y la Cámara de Diputados, y tuvo una gran difusión en medios, incluyendo Clarín, La Nación, BBC, El País, O Globo y el New York Times.

En virtud de su amplia trayectoria en la medicina, la investigación y su compromiso con las personas con discapacidad, lo hacen merecedor de la distinción de Ciudadano Ilustre de nuestra Ciudad, cumpliendo los requisitos estipulados por la Ley 578. Para mayores precisiones, se acompaña su curriculum vitae.

Por lo expuesto, solicito al Cuerpo Legislativo, la consideración y aprobación del proyecto de Ley que se acompaña.

Sin otro particular, saludo muy atentamente.

CARGOS PASADOS & ACTUALES

Director Científico
Fundación INFANT
Gavilán 94, CABA, CP1406

Cesar Milstein Chair
Profesor titular con Tenure
Vanderbilt Vaccine Center
Departamento de Pediatría, Universidad de Vanderbilt
Nashville, Tennessee, EE. UU.

Fundador
Restaurante Alamesa
Buenos Aires, Argentina

EDUCACIÓN

Colegio Nacional de Buenos Aires, Universidad de Buenos Aires, Argentina – Bachiller (1985)
Facultad de Medicina, Universidad de Buenos Aires, Argentina – Médico (1990)

RECONOCIMIENTOS

1. Comités, Premios y Distinciones Académicas

1990 – Graduado con Honores, Facultad de Medicina, Universidad de Buenos Aires

1995 – Representante del plantel de residentes médicos, Junta del Instituto de Investigación, William Beaumont Hospital, Royal Oak, Michigan, EEUU

1997 – Premio Harriet Lane a la Docencia, Departamento de Pediatría, Johns Hopkins Hospital, Baltimore, Maryland, EEUU

1998 – Premio Pasteur Mérieux Connaught, Infectious Diseases Society of America, EEUU

2001 – Premio Thomas & Carol McCann, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, EEUU

2004 – Revisor Ad-Hoc del Red Book (27.^a ed.), Academia Americana de Pediatría, EEUU

2004 – Revisor de Subvenciones de Salud Pública del Ministerio de Relaciones Exteriores, Copenhagen, Dinamarca

2005 – Asesor Temporal, Organización Mundial de la Salud, Iniciativa de Entornos Saludables para Niños, Buenos Aires, Argentina

2006 – Premio al Mejor Investigador Joven de EEUU, Society for Pediatric Research, EEUU

2007 – Asesor y miembro del Comité de Ciencias Médicas, CONICET, Argentina

2007 – Miembro del Comité del Thrasher Research Fund, Salt Lake City, Utah, EE. UU.

2008 – Premio Luis Pasteur, Academia Nacional de Medicina, Argentina

2009 – Titular de la Catedra Honoraria César Milstein en Vacunología Pediátrica, Vanderbilt University, Nashville, TN, EEUU

2009 – Personalidad Destacada en Ciencia, Legislatura de la Ciudad de Buenos Aires

2009 – Revisor del Burroughs Welcome Foundation, United Kingdom

2009 – Revisor del Special Challenges Award, National Institute of Allergy and Infectious Diseases, NIH, EE. UU.

2009 – Study Section Member, National Institute of Allergy and Infectious Diseases, NIH, EE. UU.

2010 –E. Mead Johnson Award al Mejor Investigador Pediatrico, Sociedad For Pediatric Research, EEUU

2010 – Revisor, Consejo Nacional de Investigación Médica y de Salud (NHMRC), Australia

2011 – Miembro, American Society for Clinical Investigation

2011 – Doctor Honoris Causa, Universidad Peruana Antenor Orrego, Perú

2012 – Miembro Ad-Hoc, Board of Scientific Counselors, National Institute of Allergy and Infectious Diseases, NIH

2013 – Miembro, American Pediatric Society

2013 – Miembro del Comité de Evaluación de Desarrollo de Vacunas, National Institute of Allergy and Infectious Diseases, NIH

2013 – Miembro del Comité Científico, Thrasher Research Fund, Salt Lake City, Utah, EEUU

2014 – Premio de Derechos Humanos, B’Nai Brith Argentina

2014 – Fellow, American Academy for Advancement of Science

2014 – Miembro, Comité Asesor de Desarrollo de Productos para Vacunas, OMS, Ginebra

2014-2015 – Miembro del Grupo de Trabajo de Inmunización Materna, NVAC, NIH

2015 – Profesor Honorario, Universidad Maimónides, Buenos Aires, Argentina

2015 – Miembro del Comité de Vigilancia de virus sincicial respiratorio, Organización Mundial de la Salud, Ginebra, Suiza

2016 – Miembro del Comité de Desarrollo de Vacunas, Organización Mundial de la Salud, Ginebra, Suiza

2016 – Miembro del Directorio de la International RSV Society

2016 – Miembro, Consejo Presidencial Argentina 2030

2017 – Miembro del Comité de Desarrollo de Productos para Vacunas, Organización Mundial de la Salud, Ginebra, Suiza

2017 – Consultor, Comité Asesor sobre Vacunas y Productos Biológicos Relacionados (VRBPAC), FDA, EE. UU.

2021 – Seleccionado entre los 200 Graduados más Prestigiosos, Universidad de Buenos Aires

2023 – Premio Konex, Argentina

2025 – Premio Salud – Universidad de Ciencias Empresariales y Sociales, Buenos Aires, Argentina

2. Premios y Distinciones Sociales – Alamesa

2024 – Premio a la Innovación al Servicio de la Comunidad – VISA/La Nación

2024 – Premios Obrar Oro a Pyme – OBRAR

2024 – Premio iSalud – Innovación en Salud – iSalud

2024 – Declarado de Interés de la Honorable Cámara de Senadores de la Nación, República Argentina

2024 – Reconocimiento Especial por Aporte a la Inclusión Laboral de Personas con Discapacidad, Consejo Publicitario Argentino

2024 - Premio Perfil al Mejor Aporte en Organizaciones de la Sociedad Civil – Perfil

2024 – Reconocimiento de la Honorable Cámara de Diputados de la Nación, República Argentina

2024 – Laurel de Plata, Rotary Club, Buenos Aires, Argentina

2024 – Declaración de Interés Social, Legislatura de la Ciudad de Buenos Aires

2024 – Reconocimiento de la Secretaria de Turismo, Ente de Turismo de Buenos Aires

2024 – Emprendedor Social del Año, Ernst & Young

2025 – Marca País, Republica Argentina

2025 – Mención Especial, Premios Buenos Aires Diseña, GCBA

2025 – Premio Educación e Inclusión – Pollera, Pantalón - Mujeres que van por Mas

2025 – Premio a la Innovación al Servicio de la Comunidad – VISA-La Nacion

2025 – Empresa B Certificada, Sistema B

2025 - Premio a la Labor por los Derechos Humanos , Observatorio de DDHH del Senado de la Nación, República Argentina

3. Premios & Nominaciones Documental – Alamesa

- Festival Internacional de Cine de Ponferrada, Ponferrada, **España (premiado)**
- NanoCon International Film Festival, Washington, **Estados Unidos (premiado)**
- Job Film Days, Museo Nacional de Cine de Torino, **Italia**

- Latino & Native American Film Festival, Connecticut, **Estados Unidos**
- Festival de Cinema de Girona, **España**
- Tangier International Film Festival, Tánger, **Marruecos**
- Muestra de Cine Social “La Imagen del Sur”, Córdoba, **España**
- We Care Filmfest, Goa, **India**
- Premios PRODU, Mejor Contenido/Programa que Promueve la Diversidad, **Estados Unidos (premiado)**
- SP Food Film Fest, São Paulo, **Brasil**

SELECCION DE COMENTARIOS DE PERIODICOS INTERNACIONALES SOBRE ALAMESA

- Alamesa es un oasis. **THE NEW YORK TIMES, EEUU**
- Un proyecto con sentido de inclusión como pocos en el mundo. **BBC NEWS, UK**
- Una cocina sin fuegos ni cuchillos ni balanzas se convierte en una poderosa herramienta de inclusión aplaudida por el papa Francisco. **DIARIO EL PAIS, ESPANA**
- El desafío es que experiencias como ésta puedan replicarse. **CNN ESPANOL, EEUU**
- La oportunidad de ser feliz, tener trabajo, y sentirse pleno en la vida. **OGLOBO, BRASIL**

- Un lenguaje de colores e hilos invisibles para el cliente que permiten a los trabajadores de Alamesa poder hacer su trabajo sin estrés. **AGENCIA EFE, ESPANA**

FORMACIÓN DE POSGRADO Y ENTRENAMIENTO EN FELLOWSHIPS

- Departamento de Pediatría, Hospital Francés, Universidad de Buenos Aires, Argentina
- Internado y Residencia (1991–1993)
- Departamento de Pediatría, Hospital William Beaumont, Michigan, EE. UU. – Internado y Residencia (1993–1996)
- División de Enfermedades Infecciosas Pediátricas, Departamento de Pediatría, Universidad Johns Hopkins, Maryland – Fellow Postdoctoral (1996–1999)

NOMBRAMIENTOS ACADÉMICOS

- 1999–2006 – Profesor Asistente, División de Enfermedades Infecciosas, Departamento de Pediatría, Facultad de Medicina, Universidad Johns Hopkins
- 2003–2023 – Director Científico, Fundación INFANT, Buenos Aires
- 2006–2009 – Profesor Asociado, División de Enfermedades Infecciosas, Departamento de Pediatría, Universidad Johns Hopkins
- 2006–2009 – Director, Red Panamericana de Infancia, Universidad Johns Hopkins
- 2009–2011 – Profesor Asociado, División de Enfermedades Infecciosas, Departamento de Pediatría, Universidad Vanderbilt
- 2009–2016 – Titular de la Cátedra César Milstein, Vanderbilt Vaccine Center, Universidad Vanderbilt
- 2011–2016 – Profesor Titular, División de Enfermedades Infecciosas, Departamento de Pediatría, Universidad Vanderbilt

NOMBRAMIENTOS CONJUNTOS

- 2000–2009 – Departamento de Microbiología Molecular e Inmunología, Escuela de Salud Pública, Universidad Johns Hopkins

- 2001–2009 – Departamento de Salud Internacional, Escuela de Salud Pública, Universidad Johns Hopkins

ACTIVIDADES EDUCATIVAS

Instrucción en Aula y Clínica:

- 1999–2003 – Ciclo de conferencias sobre enfermedades infecciosas pediátricas para residentes, Universidad Johns Hopkins
- 2003 – Instructor clínico para estudiantes de medicina, Universidad Johns Hopkins
- 2007–Presente – Codirector, Pasantía en Ciencias de la Salud Traslacional en Argentina, Universidad de Georgetown

Educación Médica Continua (CME):

- 1999 – “Vacunas para el siglo XXI”, Universidad Johns Hopkins – Disertante
- 2000 – “Vacunas respiratorias para el próximo siglo”, Universidad Johns Hopkins – Disertante
- 2000 – “Manejo antibiótico de la otitis media”, Universidad Johns Hopkins – Disertante
- 2002 – “Vacunas en el siglo XXI”, Universidad Johns Hopkins – Disertante
- 2004 – “Maduración de anticuerpos y su rol en la protección inmunológica”, Conferencia Anual de Investigación en Vacunas, Fundación Nacional para Enfermedades Infecciosas – Disertante
- 2004 – “Enfermedades agravadas por vacunas contra paramixovirus”, Conferencia Interscience sobre Agentes Antimicrobianos y Quimioterapia – Disertante
- 2007 – “El metapneumovirus humano”, Universidad Johns Hopkins – Disertante

MENTORÍAS

Docentes

- Kathryn Miller, MD (EE.UU.) – Profesora Asistente, Universidad Vanderbilt
- Guillermina A. Melendi, MD (EE.UU./Argentina) – Investigadora Asistente, Fundación INFANT
- Laura Talarico, PhD (Argentina) – Investigadora Junior, CONICET
- Romina P. Libster, MD – Profesora Adjunta Asistente, Universidad Vanderbilt; Investigadora Junior, Fundación INFANT
- Patricio L. Acosta, PhD (Argentina) – Investigador Junior, CONICET
- Mauricio T. Caballero, MD (Argentina) – Investigador Adjunto, Fundación INFANT
- Gastón Ofman, MD (Argentina) – Profesor Asistente, Universidad de Alabama
- Damián Alvarez Paggi (Argentina) – Investigador Adjunto, CONICET

POSTDOCTORALES

- Dario R. Lirman, MD – Residente, Children's Hospital of Pennsylvania
- Federico R. Laham, MD – Residente, Jackson Hospital, Universidad de Miami
- Maria Elina Serra, MD – Vicedirectora Médica, Unitrials S.A., Buenos Aires
- Maria Ines Klein, MD – Directora, INFANT Andes, Neuquén
- Guillermina A. Melendi, MD – Investigadora, Fundación INFANT
- Niranjana Bhat, MD – Profesor Asistente, Universidad Johns Hopkins
- Johanna Hernandez, MD – Fundación INFANT
- Romina Libster, MD – Fundación INFANT
- Jimena Bugna Hortonedo, MD – Fundación INFANT
- Maria Florencia Delgado, PhD – Fundación INFANT
- Georgina Di Gennaro, MD – Fundación INFANT
- Martin Ferolla, MD – Fundación INFANT
- Diego Hijano, MD – Universidad Vanderbilt
- Mauricio Caballero, MD – Fundación INFANT
- Cecilia Mateu, PhD – Fundación INFANT
- Marina Fernandez, MD – Fundación INFANT
- Stella Maris Zanone, MD – Fundación INFANT
- Ana Ortigoza, MD – Fundación INFANT
- Carla Simonetto, MD – Fundación INFANT
- Sarah Geoghegan – Fundación INFANT

PREDOCTORALES

Incluye a Maria Florencia Delgado, Maria Paula Schiatti, Silvina Coviello, Ana Clara Monsalvo, Juan Pío Batalle, Paula Scalzo, Patricio Acosta, Maria Florencia López, Lucas Fleuren, Colby Passaro, Jennifer Falconier, Sofía Aranda, Sofía Jares Baglivo, Clara Sanchez Yanotti, Sofía Laudanno, Julián De Luca, Florencia Nowogrodzki, Juan Gutman, Brad Pradarelli.

COMITÉS DE TESIS

- 2002 – Sally Permar, Candidata a PhD, Universidad Johns Hopkins, Escuela Bloomberg de Salud Pública – Miembro del comité
- 2003 – Garry Blinder, Candidato a PhD, Universidad Johns Hopkins, Escuela Bloomberg de Salud Pública – Miembro del comité
- 2004 – Joshua Shinhoff, Candidato a PhD, Universidad Johns Hopkins, Escuela Bloomberg de Salud Pública – Miembro del comité
- 2015 – Alicia Ann Annamalai, Candidata a PhD, Universidad de Australia Occidental – Miembro del comité
- 2016 – Nusrat Homaira, Escuela de Pediatría, Universidad de Nueva Gales del Sur,

Sídney, Australia – Miembro del comité

ACTIVIDADES EDITORIALES

Miembro de Comité Editorial

- Environmental Health Perspectives (NIEHS)
- Journal of Clinical Investigation Insight

Revisor Ad-Hoc

Viral Immunology, European Journal of Respiratory Diseases, Journal of Virology, Journal of Pediatric Hematology and Oncology, Journal of Infectious Diseases, Microbiology and Molecular Biology Reviews, Pediatric Infectious Disease Journal, Antimicrobial Agents and Chemotherapy, Journal of Clinical Microbiology, Journal of General Virology, American Journal of Pathology, American Journal of Epidemiology, Virology, Cell Host & Microbe, Pediatrics, Vaccine, Journal of Immunology, Cell, Mucosal Immunology, Thorax, Emerging Infectious Diseases, Archives of Diseases in Childhood, Journal of Pediatrics, PLOS Pathogens, The Lancet Infectious Diseases, Journal of Clinical Investigation, Clinical Infectious Diseases, American Journal of Respiratory Critical Care Medicine, Science.

PREMIOS DE RECONOCIMIENTO ESTUDIANTIL Y POSTDOCTORAL

- 2004 – María Florencia Delgado – International Fellowship Award, American Society for Microbiology
- 2005 – María Inés Klein – Premio Sociedad Iberoamericana de Neonatología (SIBEN)
- 2005 – Federico R. Laham – American Academy of Pediatrics Research Award
- 2006 – María Inés Klein – Premio al Mejor Proyecto de Investigación, Hospital de Pediatría J.P. Garrahan
- 2007 – Niranjan Bhat – MedImmune Award, Pediatric Infectious Diseases Society
- 2008 – Guillermina A. Melendi – Early Career Research Award, Thrasher Research Fund
- 2008 – María Inés Klein – Premio Luis Pasteur, Academia Nacional de Medicina
- 2009 – Guillermina A. Melendi – Fogarty Early Career Award, NIH
- 2009 – Jimena Bugna Hortonedá – Premio Arturo Onativia, Ministerio de Salud, Argentina
- 2010 – Jimena Bugna Hortonedá – Fogarty International Clinical Research Fellows Program Award, NIH

- 2011 – Laura Talarico – Premio Bunge & Born, Argentina
- 2013 – Patricio Acosta – Young Ambassador Award, American Society for Microbiology

PROGRAMAS DE INVESTIGACIÓN Y SUBSIDIOS

1999–2004 – Coinvestigador, Bill & Melinda Gates Foundation – Desarrollo de vacuna contra el sarampión para lactantes

1999–2005 – Coinvestigador, N01AI15444 (NIAID, NIH) – Ensayos de fase 1 para vacunas contra virus respiratorios

2003–2006 – IP, Fundación INFANT – Rol de la inmunidad innata en la severidad del RSV

2004–2007 – Coinvestigador, Gates Foundation – Modelo de fiebre hemorrágica por dengue en macacos rhesus

2004–2005 – IP, R21AI54952 (NIH) – Patogénesis del agravamiento por vacuna del RSV

2005–2010 – IP, R01AI54952 (NIH) – Continuación del estudio anterior

2007–2009 – IP, Thrasher Research Fund – Metapneumovirus humano en exacerbaciones asmáticas

2007–2012 – IP, NIEHS – Genes antioxidantes y enfermedades respiratorias en neonatos prematuros

2008–2011 – IP, UBS/Optimus Foundation – Investigación sobre fiebre hemorrágica por dengue

2008–2013 – IP, SeCyT/Ministerio de Salud de Argentina – Programa de enfermedades respiratorias pediátricas

2010–2011 – IP, Abbott Nutrition – Componentes de leche materna e interferones tipo I frente a RSV/influenza

2011–2013 – IP, Gates Foundation – Carga de enfermedad por RSV

2011–2014 – IP, Thrasher – Bancos de leche humana y enfermedades pulmonares en prematuros

2012–2015 – IP, UBS – Carga de dengue primario en lactantes argentinos

2013–2014 – IP, R56AI104853 (NIH) – Diseño racional de vacuna contra RSV para prevención de asma

2013–2016 – IP, UBS – Dengue en población infantil vulnerable

2013–2016 – IP, Gates Foundation – Consecuencias a largo plazo del RSV

2014–2016 – Co-IP, Gates Foundation – Biomarcadores y predictores de severidad de RSV

2015–2017 – IP, Gates Foundation – Mortalidad infantil en comunidades de bajos ingresos

2017–2019 – IP, Gates Foundation – Continuación: consecuencias a largo plazo del RSV

2017–2021 – IP, Gates Foundation – Mortalidad infantil en comunidades vulnerables

2019–2021 – IP, Merck ISS – Predictores inmunológicos y virales de sibilancias post-

RSV

2019–2020 – IP, Gates Foundation – Seguimiento post-vacunación contra RSV hasta 24 meses (M-301)

2020–2024 – IP, Gates Foundation – Eficacia del plasma hiperinmune para prevenir COVID-19 severo

COMITÉS ASESORES EN LA INDUSTRIA FARMACÉUTICA

Janssen Sciences, Janssen Global Services, MedImmune, Bavarian Nordic, Novavax, Sanofi, Mabxience, GlaxoSmithKline, Pfizer, Merck, Ablynx (Consultoría), IQVIA, Regeneron, Abbvie.

SOCIEDADES PROFESIONALES

Society for Pediatric Research, Pediatric Infectious Diseases Society, Sociedad Argentina de Pediatría, American Society for Microbiology, American Society for Clinical Investigation, American Pediatric Society, American Academy for Advancement of Science.

PUBLICACIONES [de 140, incluyendo *N Engl J Med* (11), *Lancet journals* (11), *Nature Med* (5), *Science TM* (1), *J Exp Med* (2)]

1. **Polack FP**, Tufaro PC, Viard MV, Polack NR. Pediatric Crohn's disease in an adolescent. *Arch Arg Pediatr* 1993; 91:303-307
2. **Polack FP**, Transue DJ, Belknap WM, Freij BJ, Aughton DJ. Transient elevation of sweat chloride concentration in a malnourished girl with the Mauriac syndrome. *J Pediatr* 1995; 126: 261-263
3. **Polack FP**, Freij BJ. Atypical Kawasaki disease in infants: clinical and laboratory manifestations. *Arch Arg Pediatr* 1997; 95: 39- 44
4. **Polack FP**, Coluccio M, Ruttimann R, Gaivironsky RA, Polack NR. Infected stingray injury. *Pediatr Infect Dis J* 1998, 17: 349,360
5. **Polack FP**, Harrington S, Winkelstein JA, Merz W, Willoughby RE. Recurrent Francisella philomiragia in chronic granulomatous disease *Pediatr Infect Dis J* 1998; 17: 442-443
6. Willoughby RE, **Polack FP**. Meningitis in Children. *Contemporary Pediatrics* 1998; 15: 49-70.
7. **Polack FP**, Kahn N, Maisels MJ. Changing formulas. The dance of infant formula changes. *Clin Pediatr* 1999, 38: 703-708.
8. **Polack FP**, Auwaerter PG, Lee SH, Nousari HC, Valsamakis A, Leiferman KIVI, Diwan AD, Adams RJ, Griffin DE. Atypical measles: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion inhibiting antibodies. *Nature Med* 1999; 5: 629-634.
9. Willoughby RE, **Polack FP**. What's new in meningitis in children? *Patient Care* 1999; 33: 237-54

10. **Polack FP**, Flayhart DC, Zahurak MA, Dick JD, Willoughby RE. Colonization and antibiotic resistance of *Streptococcus pneumoniae* in children infected with the human immunodeficiency virus. *Pediatr Infect Dis J* 2000; 19: 608-612.

11. **Polack FP**, Lee SH, Permar S, Manyara E, Nousari HC, Mustafa F, Valsamakis A, Adams RJ, Robinson HL, Griffin DE. DNA vaccines against measles virus: Protection associated with neutralizing antibodies against either the H or F protein in the absence of atypical measles. *Nature Med* 2000; 6: 776-781.

12. Moss WJ, **Polack FP**. Immune responses to measles and measles vaccines. Challenges for reducing measles mortality and the elimination of measles. *Viral Immunol* 2001; 14:297-309.

13. **Polack FP**, Hoffman SJ, Moss WJ, Griffin DE. Altered synthesis of interleukin-12, type 1 and type 2 cytokines in rhesus macaques during measles and atypical measles. *J Infect Dis* 2002; 15:13-19

14. **Polack FP**, Teng MN, Collins PL, Prince GA, Exner M, Regele H, Lirman DD, Rabold R, Hoffman SJ, Karp CL, Kleeberger SR, Wills-Karp M, Karron RA. A role for immune complexes in enhanced respiratory syncytial virus disease. *J Exp Med* 2002; 196: 859-65* *Science*, Editor's Choice: Oct 11,2002 & Faculty 1000, Top Ten Hidden Jewels in Microbiology 9/2002

15. **Polack FP**, Hoffman SJ, Moss WJ, Griffin DE. Cytokine responses to measles virus challenge after priming with measles DNA vaccines encoding the hemagglutinin and/or fusion protein. *J Infect Dis.* 2003; 187:1794-800.

16. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gorgone DA, Lifton MA, Williams KC, Schmitz JE, Reimann KA, Axthelm MK, **Polack FP**, Griffin DE, Letvin NL. Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. *J Virol* 2003, 77:4396-400.

17. **Polack FP**, Hoffman SJ, Crujeiras G, Griffin DE. A role for nonprotective complement fixing antibodies with low avidity for measles virus in atypical measles. *Nature Med* 2003, 9:1209-1213. *Selection in Faculty 1000

18. Hoffman SJ, **Polack FP**, Hauer D, Billiter M, Shingh M, Griffin DE. Vaccination of rhesus macaques with a recombinant measles virus expressing interleukin-12 alters humoral and cellular immune responses. *J Infect Dis.* 2003 188:1553-61
19. Hoffman SJ, **Polack FP**, Hauer D, Griffin DE. Measles virus infection of rhesus macaques affects neutrophil expression of IL-12 and IL-10. *Viral Immunol.* 2003;16: 369-79.
20. Laham FR, Israele V, Casellas JM, Garcia AM, Lac Prugent CM, Hoffman SJ, Hauer D, Thumar B, Name MI, Pascual A, Taratutto A, Ishida MT, Balduzzi M, Maccarone M , Gaivironsky RA, Karron RA; Polack NR, **Polack FP**. Differential production of inflammatory cytokines between primary infection with human metapneumovirus and other common respiratory viruses of infancy. *J Infect Dis.* 2004; 189:2047-56.
21. **Polack FP**, Karron RA. The future of RSV vaccine development. *Pediatr Infect Dis J* 2004; 23:S65-73.
22. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gorgone DA, Lifton MA, Williams KC, Schmitz JE, Reimann KA, Axthelm MK, **Polack FP**, Griffin DE, Letvin NL. Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. *J Infect Dis.* 2004; 190:998-1005.
23. Hoffman SJ, Laham FR, **Polack FP**. Mechanisms of illness during respiratory syncytial virus infection: the lungs, the virus and the immune response. *Microbes Infect.* 2004; 6:767-72.
24. Serra ME, Witeeven R, **Polack FP**. The human metapneumovirus: what impact on your patients? *Contemporary Peds* 2004; 25:18-28.
25. Delgado MF, **Polack FP**. Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease. *Expert Rev Vaccines* 2004; 3:693-700.
26. Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, **Polack FP**, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL. Identification

- of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. *J Infect Dis*. 2005; 191:1093-104.
27. Coviello S, **Polack FP**. Prophylactic and therapeutic approaches against respiratory syncytial virus. *Curr Med Chem-Anti-Infect Agents* 2005; 4:67-73
 28. **Polack FP**, Irusta PM, Hoffman SJ, Schiatti MP, Melendi GA, Delgado MF, Laham FR, Thumar B, Hendry RM, Melero JA, Karron RA, Collins PL, Kleeberger SR. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. *Proc Natl Acad Sci* 2005, 102: 8996-9001. *Selection in Faculty 1000
 29. Pan CH, Valsamakis A, Colella T, Nair N, Adams RJ, **Polack FP**, Greer CE, Perri S, Polo JM and Griffin DE. Modulation of disease, T cell responses and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. *Proc Natl Acad Sci* 2005, 102:11581-8.
 30. Klein MI, Coviello S, Bauer G, Benitez A, Serra ME, Schiatti MP, Delgado MF, Melendi GA, Novalli L, Gonzalez Pena H, Karron RA, Kleeberger SR, **Polack FP**. The impact of infection with human metapneumovirus and other respiratory viruses in young infants and children at high risk for severe pulmonary disease. *J Infect Dis* 2006, 193:1544-51.
 31. Bukreyev A, Serra ME, Laham FR, Melendi GA, Kleeberger SR, Collins PL, **Polack FP**. The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T lymphocyte response despite lacking MHC class I-restricted epitopes. *J Virol* 2006, 80:5854-61. Editor's Choice.
 32. Melendi GA, Laham FR, Monsalvo AC, Casellas JM, Israele V, Polack NR, Kleeberger SR, **Polack FP**. Virus-specific cytokine signatures in the respiratory tract during primary infection. *Pediatrics* 2007; 120: e410-5.
 33. Melendi GA, Hoffman SA, Karron RA, Irusta PM, Laham FR, Humbles A, Schofield B, Pan CH, Rabold R, Thumar B, Thumar A, Gerard NP, Mitzner W, Barnum SR, Gerard C, Kleeberger SR, **Polack FP**. C5 modulates airways hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial

- virus disease by decreasing C3a receptor expression. *J Virol* 2007; 81:991-99. Editor's Choice.
34. Melendi GA, Zavala F, Bucholz UJ, Collins PL, Kleeberger SR, **Polack FP**. Mapping and characterization of the primary and anamnestic H-2^d restricted cytotoxic T lymphocyte response against human metapneumovirus. *J Virol*. 2007; 81:11461-7.
 35. **Polack FP**. Atypical measles and enhanced respiratory syncytial virus disease made simple. *Pediatr Res* 2007; 62:111-5.
 36. Klein MI, Coviello S, Bauer G, Bergel E, Benitez A, Serra ME, Delgado MF, Schiatti MP, Melendi GA, Aspnes N, Irusta PM, Rodriguez S, Kleeberger SR, **Polack FP**. Differential gender response to the protective effect of breast milk. *Pediatrics* 2008, 121:e1510-6.
 37. Pasetti MF, Resendiz-Albor A, Ramirez K, Stout R, Papania M, Adams RJ, **Polack FP**, Ward B, Burt D, Chabot S, Ulmer J, Barry EM, Levine MM. Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques. *Clin Pharmacol Ther*. 2007; 82: 672-8.
 38. Pan CH, Nair N, Adams RJ, Zink MC, Lee EY, **Polack FP**, Singh M, O'Hagan DT, Griffin DE. Dose-dependent protection or exacerbation of disease by a PLG microparticle-adsorbed, alphavirus-based measles DNA vaccine in rhesus macaques. *Clin Vaccine Immunol*. 2008; 15:214-21
 39. Cho HY, Imani F, Miller-Degraff L, Walters D, Melendi GA, Yamamoto M, Polack FP, Kleeberger SR. Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus (RSV) Disease. *Am J Respir Crit Care Med*. 2009; 179:138-50.
 40. Delgado MF; Coviello S; Monsalvo AC; Melendi GA; Hernandez JZ; Batalle JP; Diaz L; Trento A; Chang H-Y; Mitzner W; Ravetch J; Melero JA; Irusta PM; **Polack FP**. Lack of antibody affinity maturation due to poor Toll stimulation led to enhanced RSV disease. *Nature Med* 2009;14:34-41* * Science Editor's Choice
*Nat Biotechnology Editor's Choice

41. Libster R, Bugna-Hortoned J, Laham F, Casellas JM, Israele V, Klein MI, **Polack FP**. *Pediatr Infect Dis J* 2009; 28:131-4.
42. Libster R, Bugna J, Coviello S, Hijano DR, Dunaiewsky M, Reynoso N, Cavalieri ML, Guglielmo MC, Areso MS, Gilligan T, Santucho F, Cabral G, Gregorio GL, Moreno R, Lutz MI, Panigasi AL, Saligari L, Caballero MT, Egües Almeida RM, Gutierrez Meyer ME, Neder MD, Davenport MC, Del Valle MP, Santidrian VS, Mosca G, Garcia Domínguez M, Alvarez L, Landa P, Pota A, Boloñati N, Dalamon R, Sanchez Mercol VI, Espinoza M, Peuchot JC, Karolinski A, Bruno M, Borsa A, Ferrero F, Bonina A, Ramonet M, Albano LC, Luedicke N, Alterman E, Savy V, Baumeister E, Chappell JD, Edwards KM, Melendi GA, **Polack FP**. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. *N Engl J Med*. 2010; 362:45-55.
43. Melendi GA, Coviello S, Bhat N, Zea-Hernandez J, Martin Ferolla F, **Polack FP**. Breastfeeding is associated with production of type I interferon in infants infected with influenza virus. *Acta Paediatr*. 2010; 99:1517-21
44. Bugna J, Moreno J, Sanchez S, Sanchez I, **Polack FP**. Fever and bleeding in a newborn baby. *Pediatr Infect Dis J*. 2010; 29:1153-8.
45. Libster R, Coviello S, Cavalieri ML, Morosi A, Alabart N, Alvarez L, Ferrero F, Edwards KM, **Polack FP**. Pediatric hospitalizations due to influenza in 2010 in Argentina. *N Engl J Med*. 2010; 363:2472-3.
46. Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, Hernandez JZ, Maskin B, Bugna J, Rubinstein C, Aguilar L, Dalurzo L, Libster R, Savy V, Baumeister E, Aguilar L, Cabral G, Font J, Solari L, Weller KP, Johnson J, Echavarria M, Edwards KM, Chappell JD, Crowe JE Jr, Williams JV, Melendi GA, **Polack FP**. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. *Nature Med*. 2011;17:195-9.
47. Melendi GA, Bridget D, Monsalvo AC, Laham FF, Acosta P, Delgado MF, **Polack FP**, Irusta PM. Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses. *Virus Genes*. 2011; 42:46-54
48. Miller EK, Hernandez JZ, Wimmenauer V, Shepherd BE, Hijano D, Libster R,

- Serra ME, Bhat N, Batalle JP, Mohamed Y, Reynaldi A, Rodriguez A, Otello M, Pisapia N, Bugna J, Bellabarba M, Kraft D, Coviello S, Ferolla FM, Chen A, London SJ, Siberry GK, Williams JV, **Polack FP**. A mechanistic role for type III interferon- λ 1 in asthma exacerbations mediated by human rhinoviruses. *Am J Respir Crit Care Med*. 2012;185:508-16..
49. Miller EK, Bugna J, Libster R, Shepherd BE, Scalzo PM, Acosta PL, Hijano D, Reynoso N, Batalle JP, Coviello S, Klein MI, Bauer G, Benitez A, Kleeberger SR, **Polack FP**. Human rhinoviruses in severe respiratory disease in very low birth weight infants. *Pediatrics*. 2012 Jan;129:e60-7.
 50. **Polack FP**, Lydy SL, Lee SH, Rota PA, Bellini WJ, Adams RJ, Robinson HL, Griffin DE. Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins..*Clin Vaccine Immunol*. 2013; 20:205-10.
 51. Ferolla FM, Hijano DR, Acosta PL, Rodríguez A, Dueñas K, Sancilio A, Barboza E, Caría A, Gago GF, Almeida RE, Castro L, Pozzolo C, Martínez MV, Grimaldi LA, Rebec B, Calvo M, Henrichsen J, Nocito C, González M, Barbero G, Losada JV, Caballero MT, Zurankovas V, Raggio M, Schavlovsky G, Kobylarz A, Wimmenauer V, Bugna J, Williams JV, Sastre G, Flamenco E, Pérez AR, Ferrero F, Libster R, Grijalva CG, **Polack FP**. Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. *Am J Respir Crit Care Med*. 2013;187:983-90.
 52. Talarico LB, Bugna J, Wimmenauer V, Espinoza MA, Quipildor MO, Hijano DR, Beccaria M, Wurster V, Cavagnaro LE, Martinez D, Fattore G, Batalle JP, Acosta PL, Reynoso N, Melendi GA, Rey FA, Libster R, **Polack FP**. T helper type 2 bias and type 17 suppression in primary dengue virus infection in infants and young children. *Trans R Soc Trop Med Hyg*. 2013; 107:411-9.
 53. Ciencewicz JM, Wang X, Marzec J, Serra ME, Bell DA, **Polack FP**, Kleeberger SR. A genetic model of differential susceptibility to human respiratory syncytial virus (RSV) infection. *FASEB J*. 2014; 28:1947-56.
 54. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, Anovadiya AP, Azziz-Baumgartner E, Báez C, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Denholm JT, Dominguez SR, Duarte PA, Dubnov-Raz G, Echavarria M,

- Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Iglesias AL, Hoger PH, Hu X, Islam QT, Jiménez MF, Kandeel A, Keijzers G, Khalili H, Knight M, Kudo K, Kuszniarz G, Kuzman I, Kwan AM, Amine IL, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Mayo-Montero E, McGeer A, Memish Z, Metan G, Mickiene A, Mikić D, Mohn KG, Moradi A, Nymadawa P, Oliva ME, Ozkan M, Parekh D, Paul M, **Polack FP**, Rath BA, Rodríguez AH, Sarrouf EB, Seale AC, Sertogullarindan B, Siqueira MM, Skręt-Magierło J, Stephan F, Talarek E, Tang JW, To KK, Torres A, Törün SH, Tran D, Uyeki TM, Van Zwol A, Vaudry W, Vidmar T, Yokota RT, Zarogoulidis P; PRIDE Consortium Investigators, Nguyen-Van-Tam JS. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. *Lancet Respir Med*. 2014; 2:395-404.
- 55 Scotta MC, Veras TN, Klein PC, Tronco V, **Polack FP**, Mattiello R, Pitrez PM, Jones MH, Stein RT, Pinto LA. Impact of 10-valent pneumococcal non-typeable *Haemophilus influenzae* protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction. *Vaccine*. 2014 Jul; 32:4495-9.
- 56 Coviello S, Wimmenauer V, **Polack FP**, Irusta PM. Bacterial lysates improve the protective antibody response against respiratory viruses through Toll-like receptor 4. *Hum Vaccin Immunother*. 2014;10:2896-902.
- 57 García LN, Leimgruber C, Uribe Echevarría EM, Acosta PL, Brahamian JM, **Polack FP**, Miró MS, Quintar AA, Sotomayor CE, Maldonado CA. Protective phenotypes of club cells and alveolar macrophages are favored as part of endotoxin-mediated prevention of asthma. *Exp Biol Med* (Maywood). 2015; 240:904-16.
- 58 Caballero MT, Serra ME, Acosta PL, Marzec J, Gibbons L, Salim M, Rodriguez A, Reynaldi A, Garcia A, Bado D, Buchholz UJ, Hijano DR, Coviello S, Newcomb D, Bellabarba M, Ferolla FM, Libster R, Berenstein A, Siniawski S, Blumetti V, Echavarria M, Pinto L, Lawrence A, Ossorio MF, Grosman A, Mateu CG, Bayle C, Dericco A, Pellegrini M, Igarza I, Repetto HA, Grimaldi LA, Gudapati P, Polack NR, Althabe F, Shi M, Ferrero F, Bergel E, Stein RT, Peebles RS, Boothby M, Kleeberger SR, **Polack FP**. TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization. *J Clin Invest*. 2015; 125:571-82.

- 59 Larkin EK, Gebretsadik T, Moore ML, Anderson LJ, Dupont WD, Chappell JD, Minton PA, Peebles RS Jr, Moore PE, Valet RS, Arnold DH, Rosas-Salazar C, Das SR, **Polack FP**, Hartert TV; INSPIRE Study. Objectives, design and enrollment results from the infant susceptibility to pulmonary infections and asthma following RSV exposure study (INSPIRE). *BMC Pulm Med*. 2015;15:45
- 60 Zar HJ, **Polack FP**. Childhood pneumonia: the role of viruses. *Thorax*. 2015; 70:811-2.
- 61 **Polack FP**. The changing landscape of respiratory syncytial virus. *Vaccine*. 2015; 33:6473-8.
- 62 Libster R, Martín Ferolla F, Hijano DR, Acosta PL, Erviti A, **Polack FP**; INFANT Respiratory Network. Alcohol during pregnancy worsens acute respiratory infections in children. *Acta Paediatr*. 2015; 104:e494-9.
- 63 Mazur NI, Martín-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, Manzoni P, Mejias A, Nair H, Papadopoulos NG, **Polack FP**, Ramilo O, Sharland M, Stein R, Madhi SA, Bont L; Respiratory Syncytial Virus Network (ReSViNET). Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. *Lancet Respir Med*. 2015; 3:888-900.
- 64 Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS; WHO RSV Vaccine Consultation Expert Group. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23-24 March 2015. *Vaccine*. 2016; 34:190-7.
- 65 Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Lim WS, Al Mamun A, Anovadiya AP, Araújo WN, Azziz-Baumgartner E, Báez C, Bantar C, Barhoush MM, Bassetti M, Beovic B, Bingisser R, Bonmarin I, Borja-Aburto VH, Cao B, Carratala J, Cuezco MR, Denholm JT, Dominguez SR, Duarte PA, Dubnov-Raz G, Echavarria M, Fanella S, Fraser J, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Higuera Iglesias AL, Hoeger PH, Hoffmann M, Hu X, Islam QT, Jiménez MF, Kandeel A, Keijzers G, Khalili H, Khandaker G, Knight M, Kuszniarz G, Kuzman I, Kwan AM, Lahlou Amine I, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Manabe T, Mayo-Montero E, McGeer A, Memish ZA, Metan G, Mikić D, Mohn KG, Moradi A, Nymadawa P, Ozbay B, Ozkan M,

- Parekh D, Paul M, Poepl W, **Polack FP**, Rath BA, Rodríguez AH, Siqueira MM, Skreć-Magierło J, Talarek E, Tang JW, Torres A, Törün SH, Tran D, Uyeki TM, van Zwol A, Vaudry W, Velyvte D, Vidmar T, Zarogoulidis P; PRIDE Consortium Investigators, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. *Influenza Other Respir Viruses*. 2016;10:192-204.
- 66 Acosta PL, Caballero MT, **Polack FP**. Brief history and characterization of enhanced respiratory syncytial virus disease. *Clin Vaccine Immunol*. 2015; 23:189-95.
- 67 Zanone SM, Krause LK, Madhi SA, Bassat Q, Jha P, Simões EA, Wairagkar N, **Polack FP**; RSV and child mortality working group. Challenges in estimating RSV-associated mortality rates. *Lancet Respir Med*. 2016; 4:345-7.
- 68 Caballero MT, Jones MH, Karron RA, Hartert TV, Simões EA, Stein RT, Wairagkar N, **Polack FP**; RSV & Pediatric Asthma Working Group. The impact of respiratory syncytial virus disease prevention on pediatric asthma. *Pediatr Infect Dis J*. 2016; 35:820-2.
- 69 High M, Cho HY, Marzec J, Wiltshire T, Verhein KC, Caballero MT, Acosta PL, Ciencewicz J, McCaw ZR, Kobzik L, Miller-DeGraff L, Gladwell W, Peden DB, Serra ME, Shi M, Weinberg C, Suzuki O, Wang X, Bell DA, **Polack FP**, Kleeberger SR. Determinants of host susceptibility to murine respiratory syncytial virus (RSV) disease identify a role for the innate immunity scavenger receptor MARCO gene in human infants. *EBioMedicine*. 2016; 11:73-84.
- 70 Atwell JE, Geoghegan S, Karron RA, **Polack FP**. Clinical predictors of critical respiratory syncytial virus (RSV) illness in infants and children: data to inform case definitions for efficacy trials. *J Infect Dis*. 2016; 214:1712-1716.
- 71 Vizzotti C, Juarez MV, Bergel E, Romanin V, Califano G, Sagradini S, Rancaño C, Aquino A, Libster R, **Polack FP**, Manzur J. Impact of a maternal immunization program against pertussis in a developing country. *Vaccine*. 2016; 34:6223-6228
- 72 Geoghegan S, Erviti A, Caballero MT, Vallone F, Zanone SM, Losada JV, Bianchi A, Acosta PL, Talarico LB, Ferretti A, Grimaldi LA, Sancilio A, Dueñas K, Sastre G, Rodriguez A, Ferrero F, Barboza E, Gago GF, Nocito C, Flamenco E, Perez AR, Rebec B, Ferolla FM, Libster R, Karron RA, Bergel E, **Polack**

- FP.** Mortality due to respiratory syncytial virus: Burden and risk factors. *Am J Respir Crit Care Med.* 2017; 195:96-103
- 73 Stein RT, Bont LJ, Zar H, **Polack FP**, Park C, Claxton A, Borok G, Butylkova Y, Wegzyn C. Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis. *Pediatr Pulmonol.* 2017; 52:556-569.
 - 74 Pinto LA, De Azeredo Leitão LA, Mocellin M, Acosta P, Caballero MT, Libster R, Vargas JE, **Polack FP**, Comaru T, Stein RT, De Souza AP. IL-8/IL-17 gene variations and the susceptibility to severe viral bronchiolitis. *Epidemiol Infect.* 2017; 145:642-646.
 - 75 Schmid MA, González KN, Shah S, Peña J, Mack M, Talarico LB, **Polack FP**, Harris E. Influenza and dengue virus co-infection impairs monocyte recruitment to the lung, increases dengue virus titers, and exacerbates pneumonia. *Eur J Immunol.* 2017; 47:527-539
 - 76 Talarico LB, Batalle JP, Byrne AB, Brahamian JM, Ferretti A, García AG, Mauri A, Simonetto C, Hijano DR, Lawrence A, Acosta PL, Caballero MT, Paredes Rojas Y, Ibañez LI, Melendi GA, Rey FA, Damonte EB, Harris E, **Polack FP**. The role of heterotypic DENV-specific CD8+T lymphocytes in an immunocompetent mouse model of secondary dengue virus infection. *EBioMedicine.* 2017; 20:202-216.
 - 77 Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, **Polack FP**, Balsells E, Acacio S, Aguayo C, Alassani I, Ali A, Antonio M, Awasthi S, Awori JO, Azziz-Baumgartner E, Baggett HC, Baillie VL, Balmaseda A, Barahona A, Basnet S, Bassat Q, Basualdo W, Bigogo G, Bont L, Breiman RF, Brooks WA, Broor S, Bruce N, Bruden D, Buchy P, Campbell S, Carosone-Link P, Chadha M, Chipeta J, Chou M, Clara W, Cohen C, de Cuellar E, Dang DA, Dash-Yandag B, Deloria-Knoll M, Dherani M, Eap T, Ebruke BE, Echavarria M, de Freitas Lázaro Emediato CC, Fasce RA, Feikin DR, Feng L, Gentile A, Gordon A, Goswami D, Goyet S, Groome M, Halasa N, Hirve S, Homaira N, Howie SRC, Jara J, Jroundi I, Kartasasmita CB, Khuri-Bulos N, Kotloff KL, Krishnan A, Libster R, Lopez O, Lucero MG, Lucion F, Lupisan SP, Marcone DN, McCracken JP, Mejia M, Moisi JC, Montgomery JM, Moore DP, Moraleda C, Moyes J, Munywoki P, Mutyara K, Nicol MP, Nokes DJ, Nymadawa P, da Costa Oliveira MT, Oshitani H, Pandey N, Paranhos-Baccalà G, Phillips LN, Picot VS, Rahman M, Rakoto-Andrianarivelo M, Rasmussen ZA, Rath BA, Robinson A, Romero C, Russomando G, Salimi V, Sawatwong P, Scheltema N, Schweiger B, Scott JAG, Seidenberg P, Shen K, Singleton R, Sotomayor V, Strand TA, Sutanto A, Sylla M, Tapia MD, Thamthitiwat S, Thomas ED, Tokarz R, Turner C, Venter M, Waicharoen S, Wang J, Watthanaworawit W, Yoshida LM, Yu H, Zar HJ, Campbell H, Nair H; RSV Global Epidemiology Network. Global, regional, and national disease burden

- estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet*. 2017; 390:946-958.
- 78 Caballero MT, **Polack FP**, Stein RT. Viral bronchiolitis in young infants: new perspectives for management and treatment. *J Pediatr (Rio J)*. 2017, Aug 30
 - 79 Byrne AB, Gutierrez GF, Bruno A, Córdoba MT, Bono MM, **Polack FP**, Talarico LB, Quipildor MO. Age-associated differences in clinical manifestations and laboratory parameters during a dengue virus type 4 outbreak in Argentina. *J Med Virol*. 2017 Sep 23.
 - 80 Scheltema NM, Gentile A, Lucion F, Nokes DJ, Munywoki PK, Madhi SA, Groome MJ, Cohen C, Moyes J, Thorburn K, Thamthitiwat S, Oshitani H, Lupisan SP, Gordon A, Sánchez JF, O'Brien KL; PERCH Study Group, Gessner BD, Sutanto A, Mejias A, Ramilo O, Khuri-Bulos N, Halasa N, de-Paris F, Pires MR, Spaeder MC, Paes BA, Simões EAF, Leung TF, da Costa Oliveira MT, de Freitas Lázaro Emediato CC, Bassat Q, Butt W, Chi H, Aamir UB, Ali A, Lucero MG, Fasce RA, Lopez O, Rath BA, **Polack FP**, Papenburg J, Roglić S, Ito H, Goka EA, Grobbee DE, Nair H, Bont LJ. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. *Lancet Glob Health*. 2017; 5: e984-e991.
 - 81 Talarico LB, Byrne AB, Amarilla S, Lovera D, Vázquez C, Chamorro G, Acosta PL, Ferretti A, Caballero MT, Arbo A, **Polack FP**. Characterization of type I interferon responses in dengue and severe dengue in children in Paraguay. *J Clin Virol*. 2017; 97:10-17.
 - 82 Soto AS, Fenoy IM, Sanchez VR, March F, Perrone Sibilía MD, Aldirico MLA, Picchio MS, Arcon N, Acosta PL, **Polack FP**, Martin V, Goldman A. Toxoplasma gondii serine-protease inhibitor-1: A new adjuvant candidate for asthma therapy. *PLoS One*. 2017 Oct 26 12:e0187002
 - 83 **Polack FP**. Respiratory syncytial virus during pregnancy. *Clin Infect Dis*. 2017 Dec 15. 66:1666-1667
 - 84 Caballero MT, **Polack FP**. Respiratory syncytial virus is an "opportunistic" killer. *Pediatr Pulmonol*. 2018 Feb 20. 53: 664-667
 - 85 **Polack FP**. Crafting Live-Attenuated Vaccines Against Respiratory Syncytial Virus. *J Infect Dis*. 2018 Mar 217:1335-1337
 - 86 Caballero MT, Hijano DR, Acosta PL, Mateu CG, Marccone DN, Linder JE, Talarico LB, Elder JM, Echavarria M, Miller EK, **Polack FP**; INFANT Respiratory

- Network. Interleukin-13 associates with life-threatening rhinovirus infections in infants and young children. *Pediatr Pulmonol*. 2018 Jun 53:787-795
- 87 Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, Mejias A, Karron RA, Simões EA, Knezevic I, Ramilo O, Piedra PA, Chu HY, Falsey AR, Nair H, Kragten-Tabatabaie L, Greenough A, Baraldi E, Papadopoulos NG, Vekemans J, **Polack FP**, Powell M, Satav A, Walsh EE, Stein RT, Graham BS, Bont LJ; Respiratory Syncytial Virus Network (ReSViNET) Foundation. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. *Lancet Infect Dis*. 2018 Oct 18:e295-e311
 - 88 Rajan D, O'Keefe EL, Travers C, McCracken C, Geoghegan S, Caballero MT, Acosta PL, **Polack F**, Anderson LJ. MUC5AC Levels Associated With Respiratory Syncytial Virus Disease Severity. *Clin Infect Dis*. 2018 67:1441-1444
 - 89 Caballero MT, Bianchi AM, Nuño A, Ferretti AJP, Polack LM, Remondino I, Rodriguez MG, Orizzonte L, Vallone F, Bergel E, **Polack FP**. Mortality Associated With Acute Respiratory Infections Among Children at Home. *J Infect Dis*. 2019 219:358-364
 - 90 Paggi DA, **Polack FP** Toward Personalized Medicine in Bronchiolitis. *Am J Respir Crit Care Med*. 2019 199:1456-1458.
 - 91 **Polack FP**, Stein RT, Custovic A. The Syndrome We Agreed to Call Bronchiolitis. *J Infect Dis*. 2019 220:184-186.
 - 92 Comerlato Scotta M, Greff Machado D, Goecks Oliveira S, de Moura A, Rhoden Estorgato G, de Souza APD, Nery Porto B, de Araújo PD, Sarria EE, Pitrez PM, Jones MH, Araújo Pinto L, Tetelbom Stein R, **Polack FP**, Mattiello R. Evaluation of nasal levels of interferon and clinical severity of influenza in children. *J Clin Virol*. 2019 114:37-42.
 - 93 Hijano DR, Vu LD, Kauvar LM, Tripp RA, **Polack FP**, Cormier SA. Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity. *Front Immunol*. 2019 10:566
 - 94 Jares Baglivo S, **Polack FP**. The long road to protect infants against severe RSV lower respiratory tract illness. *F1000Res*. 2019 8. pii: F1000 Faculty Rev-610.

- 95 Aranda SS, **Polack FP**. Prevention of Pediatric Respiratory Syncytial Virus Lower Respiratory Tract Illness: Perspectives for the Next Decade. *Front Immunol*. 2019 10:1006.
- 96 Ofman G, Caballero MT, Alvarez Paggi D, Marzec J, Nowogrodzki F, Cho HY, Sorgetti M, Colantonio G, Bianchi A, Prudent LM, Vain N, Mariani G, Digregorio J, Turconi EL, Osio C, Galletti F, Quiros M, Brum A, Lopez Garcia S, Garcia S, Bell D, Jones MH, Tipple TE, Kleeberger SR, **Polack FP**. The discovery BPD (D-BPD) program: study protocol of a prospective translational multicenter collaborative study to investigate determinants of chronic lung disease in very low birth weight infants. *BMC Pediatr*. 2019 19:227
- 97 Antunes KH, Fachi JL, de Paula R, da Silva EF, Pral LP, Dos Santos AA, Dias GBM, Vargas JE, Puga R, Mayer FQ, Maito F, Zárata-Bladés CR, Ajami NJ, Sant'Ana MR, Candreva T, Rodrigues HG, Schmiele M, Silva Clerici MTP, Proença-Modena JL, Vieira AT, Mackay CR, Mansur D, Caballero MT, Marzec J, Li J, Wang X, Bell D, **Polack FP**, Kleeberger SR, Stein RT, Vinolo MAR, de Souza APD. Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response. *Nat Commun*. 2019 10:3273.
- 98 Menendez D, Snipe J, Marzec J, Innes CL, **Polack FP**, Caballero M, Schurman SH, Kleeberger SR, Resnick MA, p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus. *J Clin Invest* 2019 129:4875-4884
- 99 Jacqui Marzec, Hye-Youn Cho, Monica High, Zachary R McCaw , **Fernando Polack** , Steven R Kleeberger. Toll-like Receptor 4-mediated Respiratory Syncytial Virus Disease and Lung Transcriptomics in Differentially Susceptible Inbred Mouse Strains. *Physiol Genomics*. 2019 51:630-643.
- 100 Wang X, Li Y, O'Brien KL, Madhi SA, Widdowson MA, Byass P, Omer SB, Abbas Q, Ali A, Amu A, Azziz-Baumgartner E, Bassat Q, Abdullah Brooks W, Chaves SS, Chung A, Cohen C, Echavarria M, Fasce RA, Gentile A, Gordon A, Groome M, Heikkinen T, Hirve S, Jara JH, Katz MA, Khuri-Bulos N, Krishnan A, de Leon O, Lucero MG, McCracken JP, Mira-Iglesias A, Moisi JC, Munywoki PK, Ourohiré M, **Polack FP**, Rahi M, Rasmussen ZA, Rath BA, Saha SK, Simões EA, Sotomayor V, Thamthitiwat S, Treurnicht FK, Wamukoya M, Yoshida LM, Zar HJ, Campbell H, Nair H; Respiratory Virus Global Epidemiology Network. Global burden of respiratory infections associated with seasonal influenza in children

- under 5 years in 2018: a systematic review and modelling study. *Lancet Glob Health*. 2020 8:e497-e510.
- 101 Gaston Ofman, Brad Pradarelli, Mauricio T Caballero, Alejandra Bianchi, Luciano Alva Grimaldi, Andrea Sancilio, Karina Duenas, Andrea Rodriguez, Fernando Ferrero, Adrian Ferretti, Silvina Coviello, Fausto M Ferolla, Patricio L Acosta, Eduardo Bergel, Romina Libster, **Fernando P Polack**. Respiratory Failure and Death in Vulnerable Premature Children With Lower Respiratory Tract Illness. *J Infect Dis* 2020 PMID: 32006428 DOI: 10.1093/infdis/jiaa046
 - 102 Madhi SA, **Polack FP**, Piedra PA, Munoz FM, Trenholme AA, Simões EAF, Swamy GK, Agrawal S, Ahmed K, August A, Baqui AH, Calvert A, Chen J, Cho I, Cotton MF, Cutland CL, Englund JA, Fix A, Gonik B, Hammitt L, Heath PT, de Jesus JN, Jones CE, Khalil A, Kimberlin DW, Libster R, Llapur CJ, Lucero M, Pérez Marc G, Marshall HS, Masenya MS, Martinón-Torres F, Meece JK, Nolan TM, Osman A, Perrett KP, Plested JS, Richmond PC, Snape MD, Shakib JH, Shinde V, Stoney T, Thomas DN, Tita AT, Varner MW, Vatish M, Vrbicky K, Wen J, Zaman K, Zar HJ, Glenn GM, Fries LF; Prepare Study Group. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. *N Engl J Med*. 2020 Jul 30;383(5):426-439. doi: 10.1056/NEJMoa1908380.
 - 103 Romina Libster, Ignacio Esteban, Alejandra Bianchi, Luciano Alva Grimaldi, Karina Dueñas, Andrea Sancillo, Andrea Rodriguez, Fernando Ferrero, Katherine Stein, Patricio L Acosta, Fausto M Ferolla, Eduardo Bergel, Mauricio T Caballero, **Fernando P Polack**, INFANT Respiratory Network. Role for Maternal Asthma in Severe Human Metapneumovirus Lung Disease Susceptibility in Children. *J Infect Dis*. 2020 PMID: 31965186 PMCID: PMC7107446 DOI: 10.1093/infdis/jiaa019
 - 104 Ignacio Esteban, Renato T Stein, **Fernando P Polack**. A Durable Relationship: Respiratory Syncytial Virus Bronchiolitis and Asthma Past Their Golden Anniversary. *Vaccines (Basel)*. 2020 8(2):E201. doi: 10.3390/vaccines8020201.
 - 105 Goldin CJ, Vázquez R, **Polack FP**, Alvarez-Paggi D. Identifying pathophysiological bases of disease in COVID-19. *Transl Med Commun*. 2020;5(1):15. doi: 10.1186/s41231-020-00067-w.
 - 106 **Polack FP**, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S,

- Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577.
- 107 Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Esteban I, Caballero MT, Wood C, Berrueta M, Rondan A, Lescano G, Cruz P, Ritou Y, Fernández Viña V, Álvarez Paggi D, Esperante S, Ferreti A, Ofman G, Ciganda Á, Rodríguez R, Lantos J, Valentini R, Itcovici N, Hintze A, Oyarvide ML, Etchegaray C, Neira A, Name I, Alfonso J, López Castelo R, Caruso G, Rapelius S, Alvez F, Etchenique F, Dimase F, Alvarez D, Aranda SS, Sánchez Yanotti C, De Luca J, Jares Baglivo S, Laudanno S, Nowogrodzki F, Larrea R, Silveyra M, Leberzstein G, Debonis A, Molinos J, González M, Perez E, Kreplak N, Pastor Argüello S, Gibbons L, Althabe F, Bergel E, **Polack FP**; Fundación INFANT–COVID-19 Group. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med*. 2021 Jan 6. doi: 10.1056/NEJMoa2033700. PMID: 33406353
- 108 Pearce N, Moirano G, Maule M, Kogevinas M, Rodo X, Lawlor DA, Vandenbroucke J, Vandenbroucke-Grauls C, **Polack FP**, Custovic A. Does death from Covid-19 arise from a multi-step process? *Eur J Epidemiol*. 2021 Jan;36(1):1-9. doi: 10.1007/s10654-020-00711-7. Epub 2021
- 109 Munoz FM, Cramer JP, Dekker CL, Dudley MZ, Graham BS, Gurwith M, Law B, Perlman S, **Polack FP**, Spergel JM, Van Braeckel E, Ward BJ, Didierlaurent AM, Lambert PH; Brighton Collaboration Vaccine-associated Enhanced Disease Working Group. Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2021 23:S0264-410X(21)00094-3. doi: 10.1016/j.vaccine.2021.01.055. Online ahead of print. PMID: 33637387
- 110 Sly PD, Trottier BA, Bulka CM, Cormier SA, Fobil J, Fry RC, Kim KW, Kleeberger S, Kumar P, Landrigan PJ, Lodrop Carlsen KC, Pascale A, **Polack F**, Ruchirawat M, Zar HJ, Suk WA. The interplay between environmental exposures and COVID-19 risks in the health of children *Environ Health*. 2021 Mar 26;20(1):34. doi: 10.1186/s12940-021-00716-z. PMID: 33771185
- 111 **Fernando P Polack**, Damián Alvarez-Paggi, Romina Libster, Mauricio T Caballero, Robert V Blair, Diego R Hijano, Paola X de la Iglesia Niveyro, Daniel

- R Menendez, Wes Gladwell, Luis M Avendano, Luis Velozo, Alanna Wanek, Eduardo Bergel, Gregory A Prince, Steven R Kleeberger, Joyce Johnson, Derek Pociask, Jay K Kolls Affiliations expand. *Fatal enhanced respiratory syncytial virus disease in toddlers* Sci Transl Med . 2021 Oct 20;13(616):eabj7843. doi: 10.1126/scitranslmed.abj7843. Epub 2021 Oct 20. PMID: 34669442 DOI: 10.1126/scitranslmed.abj7843
112. Li Y, Wang X, Blau DM, Caballero MT, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet*. 2022 May 28;399(10340):2047-2064.
 113. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. Hager KJ, Pérez Marc G, Gobeil P, Diaz RS, Heizer G, Llapur C, Makarkov AI, Vasconcellos E, Pillet S, Riera F, Saxena P, Geller Wolff P, Bhutada K, Wallace G, Aazami H, Jones CE, **Polack FP**, Ferrara L, Atkins J, Boulay I, Dhaliwall J, Charland N, Couture MMJ, Jiang-Wright J, Landry N, Lapointe S, Lorin A, Mahmood A, Moulton LH, Pahmer E, Parent J, Séguin A, Tran L, Breuer T, Ceregido MA, Koutsoukos M, Roman F, Namba J, D'Aoust MA, Trepanier S, Kimura Y, Ward BJ; CoVLP Study Team. *N Engl J Med*. 2022 Jun 2;386(22):2084-2096.
 114. Löwensteyn YN, Willemsen JE, Mazur NI, Scheltema NM, van Haastregt NCJ, Buuren AAAT, van Roessel I, Scheepmaker D, Nair H, van de Ven PM, Bont LJ; on behalf of the RSV GOLD Study Group. Nosocomial RSV-related In-hospital Mortality in Children <5 Years: A Global Case Series. *Pediatr Infect Dis J*. 2023 Jan 1;42(1):1-7.
 115. Antunes KH, Stein RT, Franceschina C, da Silva EF, de Freitas DN, Silveira J, Mocellin M, Leitão L, Fachi JL, Pral LP, Gonzalez A, Oliveira S, Duarte L, Cassão G, Gonçalves JIB, Reis TM, Abbadi BL, Dornelles M, Sperotto NDM, Rigo M, Rodrigues H, Jones M, Epifanio M, Guima S, Setubal JC, Jorge TR, Mansur DS, Mayer FQ, Varela APM, Bizarro CV, Machado P, Basso LA, **Polack FP**, Custovic A, Vinolo MAR, de Souza APD. Short-chain fatty acid acetate triggers antiviral response mediated by RIG-I in cells from infants with respiratory syncytial virus bronchiolitis. *EBioMedicine*. 2022 Mar;77:103891. doi: 10.1016/j.ebiom.2022.103891. Epub 2022 Feb 24.PMID: 35220042
 116. Buendía JA, Lindarte EF, **Polack FP**. TLR4 Gene Polymorphisms Interaction With *Ascaris* Infection in Severe RSV Bronchiolitis. *Front Pediatr*. 2022 Apr

- 117,. Larcade R, DeShea L, Lang GA, Caballero MT, Ferretti A, Beasley WH, Tipple TE, Vain N, Prudent L, Lang ML, **Polack FP**, Ofman G. Maternal-Fetal Immunologic Response to SARS-CoV-2 Infection in a Symptomatic Vulnerable Population: A Prospective Cohort. *J Infect Dis.* 2022 Mar 2;225(5):800-809. doi: 10.1093/infdis/jiab591.PMID: 34865064
118. Wang X, Cho HY, Campbell MR, Panduri V, Coviello S, Caballero MT, Sambandan D, Kleeberger SR, **Polack FP**, Ofman G, Bell DA. Epigenome-wide association study of bronchopulmonary dysplasia in preterm infants: results from the discovery-BPD program. *Clin Epigenetics.* 2022 Apr 28;14(1):57. doi: 10.1186/s13148-022-01272-0.PMID: 35484630 **Free PMC article.**
119. Esteban I, Bergero G, Alves C, Bronstein M, Ziegler V, Wood C, Caballero MT, Wappner D, Libster R, Perez Marc G, **Polack FP**. Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression. *Gates Open Res.* 2022 Apr 4;5:143. doi: 10.12688/gatesopenres.13357.2. eCollection 2021.PMID: 35441127
120. Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, Baker J, Pérez Marc G, Radley D, Shittu E, Glanternik J, Snaggs H, Baber J, Zachariah P, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, **Polack FP**, Zar HJ, Staerke NB, Duron Padilla M, Richmond PC, Koury K, Schneider K, Kalinina EV, Cooper D, Jansen KU, Anderson AS, Swanson KA, Gruber WC, Gurtman A; MATISSE Study Group. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. *N Engl J Med.* 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480.
121. Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, **Polack FP**, Llapur C, Doreski PA, Ilangovan K, Rämets M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Castillo Villa G, Ingilizova M, Eiras D, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gurtman A, Gruber WC, Schmoele-Thoma B; RENOIR Clinical Trial Group. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. *N Engl J Med.* 2023 Apr 20;388(16):1465-1477. doi: 10.1056/NEJMoa2213836.

122. Löwensteyn YN, Willemsen JE, Mazur NI, Scheltema NM, van Haastregt NCJ, Buuren AAAT, van Roessel I, Scheepmaker D, Nair H, van de Ven PM, Bont LJ; on behalf of the RSV GOLD Study Group. Nosocomial RSV-related In-hospital Mortality in Children <5 Years: A Global Case Series. *Pediatr Infect Dis J*. 2023 Jan 1;42(1):1-7. doi: 10.1097/INF.0000000000003747.
122. Nurmi V, Knight C, Estcourt L, Hepojoki J, Lamikanra AA, Tsang HP, Roberts DJ, **Polack FP**, Simmonds P, Hedman K, Alvarez-Paggi D, Harvala H. The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors. *J Infect Dis*. 2023 Aug 11;228(3):245-250. doi: 10.1093/infdis/jiad070.PMID: 36967714
123. Cho HY, Wang X, Campbell MR, Panduri V, Coviello S, Caballero MT, Bennett BD, Kleeberger SR, **Polack FP**, Ofman G, Bell DA. Prospective epigenome and transcriptome analyses of cord and peripheral blood from preterm infants at risk of bronchopulmonary dysplasia. *Sci Rep*. 2023 Jul 28;13(1):12262.
124. Walsh EE, Pérez Marc G, Falsey AR, Jiang Q, Eiras D, Patton M, **Polack FP**, Llapur C, Doreski PA, Zareba AM, Ilangovan K, Rämet M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gruber WC, Schmoele-Thoma B, Gurtman A. RENOIR Trial - RSVpreF Vaccine Efficacy over Two Seasons. *N Engl J Med*. 2024 Oct 17;391(15):1459-1460.
125. Dvorkin J, Pecenka C, Sosa EM, Sancilio A, Dueñas K, Rodriguez A, Rojas-Roque C, Carruitero PB, Baral R, Vodicka E, **Polack FP**, Libster R, Caballero MT. Assessing the long-term economic impact of wheezing episodes after severe RSV disease in children from Argentina: a cost of illness analysis. *BMJ Public Health*. 2024 Jul 30;2(1):e000975. doi: 10.1136/bmjph-2024-000975.
126. Dvorkin J, Sosa E, Vodicka E, Baral R, Sancilio A, Dueñas K, Rodriguez A, Rojas-Roque C, Carruitero PB, **Polack FP**, Pecenka C, Libster R, Caballero MT. Cost of illness due to respiratory syncytial virus acute lower respiratory tract infection among infants hospitalized in Argentina. *BMC Public Health*. 2024 Feb 10;24(1):427. doi: 10.1186/s12889-024-17878-3.PMID: 38336643
127. Byrne AB, Bonnin FA, López EL, **Polack FP**, Talarico LB. C1q modulation of antibody-dependent enhancement of dengue virus infection in human myeloid cell lines is dependent on cell type and antibody specificity. **Microbes Infect**.

Capitulos de Libros

1. Goetting MG, **Polack FP**. Status Epilepticus, in Jaimovich D, Vidyasagar D(eds.). Handbook of Pediatric and Neonatal Transport Medicine. Hanley and Belfus, Philadelphia; 1996; 241-256
2. Melendi GA, **Polack FP**. The human metapneumovirus, in Jaimovich (ed.). Pediatric Infectious Diseases for the Practitioner. Editorial Panamericana, 2006.

CONFERENCIAS EN FOROS INTERNACIONALES HASTA 2019

- | | |
|-------|--|
| 1996 | Pediatric Grand Rounds, William Beaumont Hospital, Royal Oak, Michigan. Title: <i>Atypical Kawasaki disease</i> . |
| 1999 | Pediatric Grand Rounds, Johns Hopkins University, Baltimore, Maryland. Title: <i>Pathogenesis of atypical measles</i> . |
| 2001 | Pediatric Grand Rounds, University of Buenos Aires French Hospital, Buenos Aires, Argentina. Title: <i>The role of antibodies in enhanced diseases associated with inactivated paramyxovirus vaccines</i> . |
| 2001 | Gates Foundation, Consultation for a new measles vaccine, Baltimore, Maryland. Title: <i>Atypical measles: antibodies and eosinophils</i> . |
| 2002 | Pediatric Grand Rounds, Hospital Materno Infantil San Isidro, Buenos Aires, Argentina. Title: <i>Respiratory syncytial virus. Mechanisms of illness and genetic predisposition to severe lower respiratory tract disease</i> . |
| 2002. | Pediatric Grand Rounds, Hospital Frances, Buenos Aires, Argentina. Title: <i>Respiratory syncytial virus. Mechanisms of illness and genetic predisposition to severe lower respiratory tract disease</i> . |

- 2002 Biological function of antibodies. Symposium. The Henry Jackson Foundation. National Institutes of Health, Bethesda, Maryland. Title: *Role of affinity maturation in protection mediated by antibody. The atypical measles story.*
- 2002 Pulmonary Pathobiology Seminar Series, National Institute of Environmental Health Sciences, NIH, Research Triangle, North Carolina. Title: *Enhanced respiratory syncytial virus disease.*
- 2002 Pediatric Grand Rounds, William Beaumont Hospital, Royal Oak, Michigan. Title: *From a cow to the bench: designing vaccines for the 21st century.*
- 2003 Biological Sciences Research Seminar Series, University of Texas San Antonio, San Antonio, Texas. Title: *The role of complement and antibody in enhanced respiratory syncytial virus disease.*
- 2003 Pediatric Grand Rounds, Johns Hopkins University, Baltimore, Maryland. Title: *The immune system during RSV infection.*
- 2003 Pediatric Grand Rounds, Hospital de Pediatria Juan P. Garrahan, Buenos Aires, Argentina. Title: *The human metapneumovirus.*
- 2003 Pediatric Grand Rounds, Hospital Nacional Posadas, Buenos Aires, Argentina. Title: *The human metapneumovirus.*
- 2003 Congreso Argentino de Pediatría, Mar del Plata, Buenos Aires, Argentina. Title: *From a cow to the bench: designing vaccines for the 21st century.*
- 2004 Pediatric Grand Rounds, Bayview Hospital, Johns Hopkins Medical Institutions, Baltimore, Maryland. Title: *The human metapneumovirus.*
- 2004 Microbiology Seminar Series. Department of Microbiology. University of Buenos Aires, Buenos Aires, Argentina. Title: *Measles virus. Disease potentiation, immune suppression and other problems.*

- 2004 The Seventh Annual Conference on Vaccine Research. National Foundation for Infectious Diseases. Antibody maturation and its role in immune protection. Arlington, VA. Title: *The role of antibody affinity maturation in atypical measles.*
- 2004 Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Enhanced diseases caused by vaccines against paramyxoviruses. Title: *Enhanced diseases after vaccination with inactivated vaccines against paramyxoviruses.*
- 2004 Microbial Immunity and Vaccine Development Seminar Series. Bloomberg School of Public Health. Title: *Pathogenesis of enhanced respiratory syncytial virus disease: Role of complement, antibody and cellular immunity.*
- 2005 Respiratory Infections in Premature Babies and Infants. Abbott Laboratories Symposium. Buenos Aires, Argentina. Title: *The human metapneumovirus in infants and young children.*
- 2005 Pediatric Dengue Vaccine Initiative. Gates Foundation. Vail, CO. Title: *Pathogenesis of enhanced respiratory syncytial virus disease: Role of complement, antibody and cellular immunity.*
- 2005 The French Hospital Second International Pediatric Meeting, Buenos Aires, Argentina. Title: *New Vaccines: From a cow to the bench.*
- 2005 Healthy Environments, Healthy Children. World Health Organization/ National Institute of Environmental Health Sciences, Buenos Aires, Argentina. Title: *Respiratory syncytial virus pathogenesis: from bench to bedside.*
- 2006 Respiratory infections in high risk populations. Abbott Laboratories, Buenos Aires, Argentina. Title: *Role of human metapneumovirus in populations at high risk for severe lung disease.*

- 2006 Presidential Plenary. Young Investigator Award 2006. Society for Pediatric Research. Title: *Role of antibody in enhanced diseases due to paramyxoviruses.*
- 2006 Pediatric Dengue Vaccine Initiative. Gates Foundation. Arlington, MD. Title: *A rhesus macaque model of atypical measles.*
- 2006 Infectious Diseases Grand Rounds. Vanderbilt University. Nashville, TN. Title: *Respiratory syncytial virus pathogenesis. From bench to bedside.*
- 2006 Seminars in Respiratory Diseases. Laboratory of Respiratory Biology, NIEHS, NIH, Raleigh, NC. Title: *Respiratory syncytial virus pathogenesis. From bench to bedside.*
- 2006 Translational Science Seminars. Argentinean Medical Association, Buenos Aires, Argentina. Title: *Respiratory syncytial virus glycoproteins and their role in pulmonary disease.*
- 2007 Seminars in Pediatric Pulmonary Diseases. Pontificia Universidade Catolica de Porto Alegre, Porto Alegre, Brazil. Title: *Respiratory syncytial virus pathogenesis. From bench to bedside.*
- 2007 Latinoamerican Meeting on Respiratory Diseases; Rio de Janeiro, Brazil. Title: *Vaccines against respiratory syncytial virus and Impact of respiratory viruses in children.*
- 2007 Pediatric Grand Rounds. Hospital Nacional Juan Fernandez, Buenos Aires, Argentina. Title: *Respiratory syncytial virus pathogenesis. From bench to bedside.*
- 2007 Abbott European Meeting on Respiratory Diseases; Athens, Greece. Title: *Vaccines against respiratory syncytial virus.*
- 2007 6th Respiratory Syncytial Virus International Meeting. Marco Island, Florida. Title: *Respiratory syncytial virus pathogenesis. From bench to bedside.*

- 2007 International Perinatology Conference, Buenos Aires, Argentina. Title: *Development of a translational research program in a developing country.*
- 2008 University of Miami International Meeting in Infectious Diseases, Miami, FL. Title; *Bronchiolitis: the role of TLR4 and the immune system in pathogenesis.*
- 2008 FUNDASAMIN Research Symposium, Buenos Aires, Argentina. Title: *Respiratory syncytial virus pathogenesis. From bench to bedside.*
- 2008 Municipalidad de Mendoza, Mendoza, Argentina. Title: *The role of gender on breastfeeding-mediated protection.*
- 2008 Hospital San Rafael, Mendoza, Argentina. Title: *The role of gender on breastfeeding-mediated protection.*
- 2008 Argentinean Society of Virology Meeting, Buenos Aires, Argentina. Title: *Respiratory syncytial virus pathogenesis. From bench to bedside.*
- 2008 Instituto de Pesquisas, Porto Alegre, Brazil. Title: *Respiratory syncytial virus pathogenesis. From bench to bedside.*
- 2008 Resistencia Children's Hospital, Resistencia, Chaco. Title: *The role of gender on breastfeeding-mediated protection.*
- 2009 Turkish Neonatology Meeting, Izmir, Turkey. Title: *The complex relationship between RSV and asthma.*
- 2009 Abbott Neonatology Symposium, Izmir, Turkey. Title: *The role of breastfeeding in protection against respiratory diseases.*
- 2009 Oran State Hospital, Oran, Salta, Argentina. Title: *Dengue: thinking forward.*

- 2009 Bolivian-Argentinean Joint Medicine Meeting, Bermejo, Bolivia. Title: Dengue: Thinking forward.
- 2009 Wyeth-Lederle Virology Section Invited Speaker. Wyeth-Lederle, Pearl River, NY. Title: *Respiratory syncytial virus pathogenesis. From bench to bedside.*
- 2009 Jornada Brasileira da Atencao a Saude da Mulher. Porto Alegre, Brazil. Title: *Preventive role of breastfeeding against respiratory viral infections.*
- 2010 Pulmonary Grand Rounds. Vanderbilt University, Nashville, TN. Title: Pandemic influenza: impact in children and insights into pathogenesis.
- 2010 Pediatric Grand Rounds. Vanderbilt University, Nashville, TN. Title: The burden of past exposures in viral pathogenesis.
- 2010 Turkish Neonatology Congress, Badrum, Turkey. Title: Respiratory syncytial virus pathogenesis. From bench to bedside.
- 2010 Global Health Invited Speaker. Berkeley University, Berkeley, CA. Title: The role of immune complexes in viral pathogenesis.
- 2010 Presidential Plenary. E. Mead Johnson Award 2010. Society for Pediatric Research, Vancouver, Canada. Title: Respiratory infections, the burden of the past.
- 2010 XV Neonatology Meeting Santa Casa, Sao Paulo, Brazil. Title: Preventive role of breastfeeding against respiratory viral infections.
- 2010 Pediatric Experts in Pulmonology, Sao Paulo, Brazil. Title: Pathogenesis of influenza virus in children and middle age adults.
- 2010 Infectious Diseases Society of America, Vancouver, Canada. Title: Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes.

- 2010 Global Expert's Meeting, Respiratory Diseases, Barcelona, Spain. Title: Bacterial-viral interaction in respiratory diseases.
- 2010 III International Clinical Virology Symposium and Advances in Vaccines, Buenos Aires, Argentina. Title: RSV pathogenesis: from bench to bedside.
- 2010 RSV 2010 Meeting, Rotterdam, The Netherlands. Title: A role for IL-17 producing T cells in enhanced RSV disease.
- 2011 Update on respiratory diseases. Sociedad Argentina de Pediatria., Buenos Aires, Argentina. Title: Human metapneumovirus.
- 2011 Global Experts Meeting in Respiratory Diseases, Rio de Janeiro, Brazil. Title: Bacterial-viral interaction in respiratory diseases.
- 2011 IFCC-WorldLab-EuroMedLab Berlin 2011, Berlin, Germany. Title: Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes.
- 2012 Respiratory Diseases Expert Meeting. The Macrae Group. Istanbul, Turkey. Title: RSV pathogenesis: from bench to bedside.
- 2012 Pediatric Research Conference, Vanderbilt University, Nashville, TN. Title: A new public health paradigm for RSV bronchiolitis.
- 2012 The VVC-INFANT Conference, Nashville, TN. Title: Bronchiolitis and pregnant women's diet: Too sweet to be good.
- 2012 Pediatric Chairmen Conference, New Orleans, LO. Title: A new public health paradigm for RSV bronchiolitis.

- 2012 Global Experts Meeting in respiratory diseases, Abbott Pharmaceuticals, Buenos Aires, Argentina. Title: Rhinovirus is a severe pathogen for premature babies.
- 2013 Meeting of Pediatric RSV Investigators Working Group. Edinburgh, Scotland. Title: "Risk factors, incidence and mortality due to RSV associated ALRI in young children - results from study burden in Buenos Aires"
- 2013 Buenos Aires RSV Advisory Board. Abbvie - Buenos Aires, Argentina. 'Risk factors, the occurrence of respiratory syncytial virus (RSV) disease in LA and the long term sequelae'. Title: Epidemiology of RSV in Latin America"
- 2013 "Simpósio Internacional em Infecções Respiratórias na Neonatologia" São Paulo, Brazil. Title "Novos fatores de risco para bronquiolite grave"
- 2014 Vitamin D and Other Micronutrients in Maternal and Child Care Conference, Amman, Jordan. Title: "Vitamin D in the Premature Infant and Early Infancy".
- 2014 Vanderbilt Symposium on Infection and Immunity, Nashville USA Title: RSV bronchiolitis: from the lab to the field, for the kids".
- 2014 14th Brazilian Congress of Pediatric Pulmonology, Porto de Galinhas, Brazil. Title: "RSV bronchiolitis: how the environment and our genes can take our breath away".
- 2014 Society for Pediatric Research/Pediatric Academic Societies Meeting. Caroline B. Hall Symposium, Vancouver, Canada. Title: "The role of the environment in RSV disease"
- 2014 The Future of Pediatrics: From Research to Public Health Conference, Buenos Aires – Argentina. Title: "The obstetrician is the first pediatrician".
- 2014 5th International Conference on Clinical Neonatology Torino, Italy. Title: "Human milk, breastfeeding and protection against RSV infections: what do we know?"
- 2014 Clinical research in pregnant women – knowledge, gaps and opportunities Sponsored by NIH and BMGF. Bethesda, MD, USA. Title: "RSV mortality in Argentina".
- 2015 High Level Expert meeting on RSV Therapeutics ResViNet Zeist – The Netherlands. Title: "Life-threatening RSV Bronchiolitis – the need for treatment".

- 2015 RSV Workshop University of Oxford. Oxford Vaccine Group. Oxford, United Kingdom. Title: "The need for an RSV vaccine in Argentina".
- 2015 WHO Informal Consultation on surveillance for Respiratory Syncytial Virus (RSV) using the Global Influenza Programme and PIP Framework (GIP) – WHO Headquarters, Geneva, Switzerland. "Title: RSV surveillance – strategies for the future".
- 2015 NIAID/FDA RSV Workshop Bethesda, Washington, USA. Title: "Enhanced RSV disease – vaccines replicating in cytoplasm".
- 2015 Meeting of RSV Global Epidemiology Network (RSV GEN). Edinburgh, Scotland. Title: "RSV mortality in Argentina"
- 2015 RSV Asthma and Mortality Symposium , Buenos Aires, Argentina, Defining the Burden of Community-based Deaths. Title: "Defining the Burden of Community-based Deaths"
- 2015 Pontificia Universidade do Rio Grande do Sul, Porto Alegre, Brasil. Title: "RSV pathogenesis – translational programs".
- 2015 Evento Farmaco 2015, Universidad de Antioquía, Medellín, Colombia "Traslational Research in Respiratory Medicine"
- 2015 9th World Congress of the World Society for Pediatric Infectious Rio de Janeiro, Brazil, "Neonatal infections: Epidemiology and maternal vaccination"
- 2016 Minimally Invasive Tissue Sampling (MITS) and Cause of Death Ascertainment Symposium, BMGF, Barcelona, Spain. "Deaths due to Respiratory Syncytial Virus"
- 2016 2nd ReSViNET High-Level Expert Meeting, RSV workshop, Zeist, The Netherlands." Vaccines: how to look for toxicity (fetal toxicity, viral and maternal antibody interference)"
- 2016 WHO consultation on RSV vaccines. Geneva, Switzerland. Community mortality due to RSV vs recurrent wheeze. "RSV mortality in infants".
- 2016 XII Congreso Colombiano de Neumología Pediátrica y Asma Pediátrica, Bucaramanga, Colombia. "Breast feeding and prevention of acute respiratory diseases." "Die by or with RSV: infant death in South America caused by bronchiolitis." "The near future: What will happen when we have vaccines against RSV?"
- 2016 XIII Congreso SIBEN, Asuncion, Paraguay. "Breast milk, what do we know about its protective action against viral infection?" " Viral Infections and New Drugs"

- 2016 16th International RSV Symposium, Bariloche, Patagonia, Argentina. "RSV mortality in infants".
- 2016 XXII Simposio de Neumonología Pediátrica San Luis "Un lugar de Encuentro", San Luis, Argentina. "Groups at high risk for RSV severe disease"
- 2017 Asociacion Colombiana De Neumologia Pediatrica "Simposio de Actualización", Bogota, Colombia. "Career advise for young investigators"
- 2017 FDA VRBPAC Meeting. Bethesda, MD. Guest Speaker "History of Vaccine-Associated Enhanced Respiratory Syncytial Virus Disease and Characterization of Animal Models Designed to Mitigate Risk in Future Vaccine Studies".
- 2017 WHO Product Development for Vaccines Advisory Committee (PDVAC) Consultation, Geneva, Switzerland. "RSV vaccine and monoclonal antibody development"
- 2017 16th International Congress on Pediatric Pulmonology (CIPP XVI). Lisbon, Portugal. "Mortality Associated to Severe Viral Infections in Early Life", "Advances in Prevention of RSV Disease".
- 2017 XXV Curso Anual de Pediatría Práctica del HIGA Evita de Lanús, Lanus, Buenos Aires. "RSV and mortality in low income populations", Lanus, Buenos Aires
- 2017 RESVINET, Vaccines for the World III. Malaga, Spain. "Challenges in estimating infant mortality in the community due to acute respiratory infections".
- 2017 World Society of Pediatric Infectious Diseases. Shenzhen, China. "RSV vaccine development revisited".
- 2018 18th International Congress on Infectious Diseases, Buenos Aires, Argentina. "RSV Vaccine"
- 2018 17th Annual St. Jude/PIDS Pediatric Infectious Diseases Research Conference, Memphis, TN, USA. "Life after respiratory syncytial virus".
- 2018 MITS Surveillance Alliance, Barcelona
- 2018 17th International RSV Symposium, RSV 2018 Asheville NC
- 2019 WHO consultation on methodological considerations and measurement of long term sequelae related to RSV infection, Geneva.

2019 2nd Annual MITS Surveillance Alliance, Seattle

Congress/Symposium Organization

2011 Vanderbilt University & Fundacion Infant Symposium, Nashville, TN – Co-Chair

2012 Vanderbilt University & Fundacion Infant Symposium, Nashville, TN – Co-Chair

2013 Vanderbilt University & Fundación Infant Symposium, Nashville, TN – Co-Chair

2014 Vanderbilt University & Fundación Infant Symposium, Buenos Aires, Argentina - Chair

2015 Bill & Melinda Gates Foundation & Fundación Infant Expert Symposium: Role of RSV in asthma and infant mortality, Buenos Aires, Argentina. Chair.

2016 16th International RSV Symposium – RSV16, Bariloche, Patagonia, Argentina. Chair.

2017 Latin American Young Investigator's Program. Fundación INFANT, Buenos Aires, Argentina, Chair

2018 RESPIRA Latin American Program. Buenos Aires, Argentina, Chair